ARTICLE | Product Development
Slotting anti-inflammatories into COVID-19 treatment
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 19, 2020 1:11 AM UTC
Updated on Mar 25, 2020 at 10:15 PM UTC
While repurposed agents for COVID-19 have largely focused on suppressing SARS-CoV-2, there is a strong case to be made for evaluating anti-inflammatory agents in patients with severe disease.
As more emerges about the disease, it’s becoming clear that the early stage requires a different treatment strategy from the later stage, when respiratory function deteriorates...